The Food and Drug Administration says it has approved a new drug from Biogen Idec to control multiple sclerosis in adults with hard-to-treat forms of the disease.
The twice-a-day capsules, called Tecfidera, offer a new option for treating multiple sclerosis, a debilitating disease in which the body attacks its own nervous system. Biogen Idec already sells two other drugs for the disease, but both require injections.
There is no cure for multiple sclerosis and most patients experience relapses of symptoms, including loss of balance, weakness in arms and legs and blurred vision. Over time patients become weaker and less coordinated.
The FDA announced its decision on Tecfidera Wednesday.